Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) Return on Equity (2016 - 2025)

Heron Therapeutics' Return on Equity history spans 13 years, with the latest figure at 0.17% for Q4 2025.

  • For Q4 2025, Return on Equity fell 49.0% year-over-year to 0.17%; the TTM value through Dec 2025 reached 0.17%, down 49.0%, while the annual FY2025 figure was 1.06%, 64.0% up from the prior year.
  • Return on Equity reached 0.17% in Q4 2025 per HRTX's latest filing, up from 0.26% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 5.43% in Q2 2023 to a low of 582.18% in Q3 2022.
  • Average Return on Equity over 5 years is 45.83%, with a median of 0.22% recorded in 2025.
  • Peak YoY movement for Return on Equity: plummeted -58057bps in 2022, then surged 58579bps in 2023.
  • A 5-year view of Return on Equity shows it stood at 2.22% in 2021, then crashed by -337bps to 9.7% in 2022, then skyrocketed by 137bps to 3.58% in 2023, then plummeted by -91bps to 0.31% in 2024, then crashed by -156bps to 0.17% in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Return on Equity are 0.17% (Q4 2025), 0.26% (Q3 2025), and 0.04% (Q2 2025).